H.C. Wainwright analyst Brandon Folkes has reiterated their bullish stance on ENTA stock, giving a Buy rating on November 14.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Folkes has given his Buy rating due to a combination of factors that highlight Enanta Pharmaceuticals’ promising prospects. The recent positive Phase 2b RSVHR data for zelicapavir, despite not meeting the primary endpoint, showed significant efficacy in reducing RSV symptom duration, particularly in high-risk adults. This outcome suggests a strong potential for approval if these results are replicated in pivotal studies.
Additionally, Enanta’s financial position is robust, with a cash runway into FY29 and an enterprise value of approximately $110 million. The company is actively expanding its pipeline, with promising developments in pediatric RSV treatment and other therapeutic areas. These factors, combined with a proactive intellectual property strategy, reinforce the potential for substantial value growth, justifying the Buy rating and a $20 price target.
In another report released on November 14, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $17.00 price target.